POMDOCTOR Ltd income statement POM

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, POMDOCTOR Ltd reported revenue of $57.2 million. It recorded a net loss of $18.7 million. The operating loss came to $17.0 million, an operating margin of -29.7%. Diluted earnings per share were -$3.14.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Revenue
57
Cost of revenue
50
Gross profit
7
Research and development
2
Selling, general and administrative
22
Operating income
-17
Other income (expense)
-2
Pretax income
-19
Income tax
0
Net income
-19
Net income to common
-30
Basic EPS
-3.14
Diluted EPS
-3.14
Weighted average shares, basic
10
Weighted average shares, diluted
10
Other measures
Depreciation and amortization
0
EBITDA
-17
Margins
Gross margin
13.07%
Operating margin
-29.67%
Pretax margin
-32.74%
Profit margin
-32.74%
EBITDA margin
-29.63%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Retail-Miscellaneous Retail (SIC 5900)
Listed as
POM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Guangzhou
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1877971

Other Retail-Miscellaneous Retail companies

All 23 Retail-Miscellaneous Retail companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.